195rar -

SYK must physically touch FLT3 to activate it.

Because this specific interaction is so vital for the cancer to progress, it identified a new potential "weak spot" that future drugs could target to treat AML more effectively. 195rar

When the researchers used the SYK mutant with the change, the protein could no longer bind to FLT3. This was a "Eureka" moment because it proved: SYK must physically touch FLT3 to activate it

In a study published in , scientists investigated a protein called SYK (Spleen Tyrosine Kinase). They knew SYK was present in blood cancers but weren't sure exactly how it contributed to the disease. They discovered that SYK acts as a "partner in crime" with another protein called FLT3 , which is frequently mutated in leukemia patients. The 195RAR Mutation This was a "Eureka" moment because it proved:

By changing a specific sequence of amino acids from to GAL , researchers created a mutant version of the protein.

This tiny change—the mutation—acted like changing the shape of a key so it no longer fits a lock. What the Story Revealed

Highly active SYK can help cancer cells ignore standard treatments meant to kill FLT3-driven leukemia.